This is a repository copy of *Using electronic health records to predict costs and outcomes in stable coronary artery disease.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/95319/

Version: Published Version

**Article:**
Asaria, Miqdad orcid.org/0000-0002-3538-4417, Walker, Simon Mark orcid.org/0000-0002-5750-3691, Palmer, Stephen John orcid.org/0000-0002-7268-2560 et al. (8 more authors) (2016) Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart. ISSN 1355-6037

https://doi.org/10.1136/heartjnl-2015-308850

---

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
ABSTRACT

Objectives To use electronic health records (EHR) to predict lifetime costs and health outcomes of patients with stable coronary artery disease (stable-CAD) stratified by their risk of future cardiovascular events, and to evaluate the cost-effectiveness of treatments targeted at these populations.

Methods The analysis was based on 94 966 patients with stable-CAD in England between 2001 and 2010, identified in four prospectively collected, linked EHR sources. Markov modelling was used to estimate lifetime costs and quality-adjusted life years (QALYs) stratified by baseline cardiovascular risk.

Results For the lowest risk tenth of patients with stable-CAD, predicted discounted remaining lifetime healthcare costs and QALYs were £62 210 (95% CI £53 724 to £70 943) and 12.0 (95% CI 11.5 to 12.5) years, respectively. For the highest risk tenth of the population, the equivalent costs and QALYs were £35 549 (95% CI £31 679 to £39 615) and 2.9 (95% CI 2.6 to 3.1) years, respectively. A new treatment with a hazard reduction of 20% for myocardial infarction, stroke and cardiovascular disease death and no side-effects would be cost-effective if priced below £72 per year for the lowest risk patients and £646 per year for the highest risk patients.

Conclusions Existing EHRs may be used to estimate lifetime healthcare costs and outcomes of patients with stable-CAD. The stable-CAD model developed in this study lends itself to informing decisions about commissioning, pricing and reimbursement. At current prices, to be cost-effective some established as well as future stable-CAD treatments may require stratification by patient risk.

INTRODUCTION

Cardiovascular disease (CVD) is a leading cause of mortality in England with approximately a third of all deaths attributed to it. The combination of an ageing population and improvements in survival after acute coronary syndrome has resulted in a large and growing number of patients with stable coronary artery disease (stable-CAD). CVD has, therefore, also become a major source of morbidity and healthcare resource use: there are >5 million people living with CVD in England costing the National Health Service (NHS) more than £30 billion per year. The stable-CAD population serves as an important example of a patient population suffering from a long-term condition.
Collaboration. CALIBER links primary care data from the Clinical Practice Research Datalink with EHR from the Myocardial Ischaemia National Audit Project Registry, hospital inpatient records from Hospital Episode Statistics and cause-specific mortality from the Office for National Statistics. The CALIBER dataset has been described in detail by Denaxas et al. Patients with stable-CAD were defined as those patients in the CALIBER dataset who were event free for at least 6 months after having had unstable angina, ST elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) or those patients with stable angina or other coronary heart disease (CHD) diagnoses. The median follow-up of these patients was 4.2 (IQR 1.9–6.9) years, during which 16,783 patients died and 8,203 patients experienced one or more non-fatal coronary outcomes.

Endpoints
The primary clinical endpoints were first occurrences of non-fatal myocardial infarction (MI), ischaemic stroke and haemorrhagic stroke, as well as CVD and non-CVD mortality. Other clinical endpoints were CVD and non-CVD mortality following a non-fatal event. These were combined to produce the primary economic outputs from the model which were quality-adjusted life years (QALYs) as well as total and CVD-specific costs, each predicted over the remaining lifetime of the patient. The model was also used to produce estimates of event rates and disease progression over time stratified by baseline CVD risk.

Model
A state transition model (shown in figure 1) was developed to capture the natural history of patients with stable-CAD. The structure of the model was determined with reference to both previous models in CVD and expert clinical advice. All patients entered the model in the stable-CAD state and progressed through the model until they experienced either CVD or non-CVD mortality. The time horizon of the model was, therefore, the patient’s remaining lifetime. The model captured time varying and age-dependent risks, costs and health-related quality of life (HRQoL) in 90-day segments. Costs and HRQoL were attached to model states and, in order to stratify by patients’ baseline risk, adjusted for patient covariates at baseline as well as for age and for time elapsed following non-fatal events. Model predicted costs, life years and QALYs were discounted at 3.5% per annum in keeping with the guidelines in England. While only first occurrences of non-fatal CVD events were explicitly modelled, further non-fatal events were implicitly captured in the time varying risk, cost and HRQoL estimates.

Statistical modelling of risk equations
Rapsomaniki et al. developed, tested and validated a range of prognostic models for patients with stable-CAD using the CALIBER dataset. We built on their recommended prognostic model, using it as the basis for the risk equations underpinning the prediction of the five primary clinical endpoints. Using the prognostic factors and missing data imputation algorithm of Rapsomaniki et al. we estimated various parametric survival models (generalised gamma, lognormal, Weibull, exponential) for each of the five endpoints. For each endpoint the best fitting parametric model was selected as determined by the Akaike information criteria. Predictions resulting from the selected models were assessed for plausibility by clinical experts (AT, CPG, ADS, HH). Key prognostic factors included in the models were demographic measures (age, sex, social deprivation), stable-CAD subtype (stable angina, unstable angina, STEMI, NSTEMI and other CHD), use of long-acting nitrates, whether coronary artery bypass graft or percutaneous coronary intervention (PCI) had been performed in the 6 months following CAD diagnosis, previous MI, smoking, blood pressure, diagnosis of hypertension, diabetes, lipids,

Figure 1  Structure of the Markov model and the role played by the 11 risk equations that we use to model disease progression.

CVD comorbidities (heart failure, peripheral arterial disease, atrial fibrillation, stroke), non-CVD comorbidities (chronic renal disease, chronic obstructive pulmonary disease, cancer, chronic liver disease), psychosocial factors (depression, anxiety) and clinically assessed biomarkers (heart rate, white cell count, haemoglobin, creatinine).

Risk equations for the six subsequent events, namely, CVD and non-CVD mortality following non-fatal MI, ischaemic stroke and haemorrhagic stroke, were estimated in a similar way. However, due to the greatly reduced numbers of events observed, these use only sex and age at time of non-fatal event as covariates. Non-CVD mortality beyond the maximum

### Table 1  Patient characteristics by risk group

<table>
<thead>
<tr>
<th>Risk group</th>
<th>Lowest risk</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>Highest risk</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients in dataset</td>
<td>10 035</td>
<td>9903</td>
<td>9797</td>
<td>9626</td>
<td>9516</td>
<td>9455</td>
<td>9382</td>
<td>9335</td>
<td>9249</td>
<td>8668</td>
<td>94 966</td>
</tr>
<tr>
<td>5-year risk (%; average across patients)</td>
<td>3.69</td>
<td>5.70</td>
<td>7.37</td>
<td>9.15</td>
<td>11.20</td>
<td>13.71</td>
<td>17.14</td>
<td>22.14</td>
<td>30.42</td>
<td>52.37</td>
<td>16.68</td>
</tr>
<tr>
<td>5-year risk (%; at average covariate values)</td>
<td>3.46</td>
<td>5.43</td>
<td>6.95</td>
<td>8.53</td>
<td>10.36</td>
<td>12.57</td>
<td>15.64</td>
<td>20.07</td>
<td>27.23</td>
<td>44.18</td>
<td>11.64</td>
</tr>
</tbody>
</table>

Sociodemographic characteristics

Sex (% female) | 64 | 48 | 42 | 39 | 37 | 38 | 37 | 38 | 42 | 44 | 46 | 44 |
Age (years if male) | 49 | 55 | 59 | 62 | 65 | 67 | 71 | 74 | 77 | 81 | 67 |
Age (years if female) | 53 | 62 | 67 | 70 | 73 | 75 | 78 | 80 | 83 | 87 | 72 |
Age (weighted average) | 52 | 59 | 62 | 65 | 68 | 70 | 73 | 76 | 80 | 84 | 69 |
Most deprived quintile (%) | 15 | 17 | 18 | 19 | 20 | 21 | 21 | 22 | 24 | 22 | 20 |

Stable-CAD diagnosis (%)

NSTEMI | 0 | 1 | 3 | 5 | 8 | 10 | 12 | 17 | 23 | 43 | 10 |
STEMI | 1 | 4 | 8 | 12 | 13 | 14 | 13 | 9 | 6 | 4 | 7 |
Unstable angina | 10 | 13 | 12 | 12 | 12 | 12 | 13 | 15 | 17 | 15 | 14 |
Stable angina | 78 | 65 | 56 | 49 | 43 | 39 | 37 | 34 | 29 | 18 | 47 |
Non-specific CHD | 11 | 17 | 20 | 22 | 24 | 25 | 26 | 25 | 20 | 23 |

Stable-CAD severity (%)

PCI in past 6 months | 9 | 12 | 13 | 14 | 13 | 11 | 9 | 6 | 4 | 9 |
CABG in past 6 months | 9 | 7 | 6 | 5 | 5 | 4 | 4 | 3 | 2 | 1 | 4 |
Previous/recurrent MI | 2 | 6 | 10 | 14 | 18 | 23 | 29 | 29 | 32 | 43 | 18 |
Use of nitrates | 10 | 16 | 19 | 21 | 24 | 28 | 33 | 37 | 43 | 56 | 28 |

CVD risk factors

Smoking status (%)

Current smoker | 31 | 35 | 36 | 37 | 38 | 38 | 37 | 35 | 32 | 30 | 35 |
Ex-smoker | 27 | 30 | 31 | 32 | 32 | 33 | 34 | 34 | 34 | 34 | 32 |
Never smoked | 41 | 35 | 33 | 31 | 30 | 29 | 29 | 31 | 33 | 36 | 33 |
Hypertension (%) | 69 | 70 | 71 | 71 | 72 | 74 | 76 | 79 | 83 | 87 | 76 |
Diabetes (%) | 4 | 8 | 10 | 12 | 14 | 16 | 18 | 21 | 24 | 32 | 16 |
Total cholesterol (mmol/L) | 4.95 | 4.91 | 4.84 | 4.79 | 4.74 | 4.74 | 4.74 | 4.70 | 4.68 | 4.64 | 4.54 | 4.79 |
HDL (mmol/L) | 1.41 | 1.37 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.36 | 1.37 | 1.37 | 1.37 |

CVD comorbidities (%)

Heart failure | 5 | 7 | 9 | 12 | 15 | 19 | 27 | 37 | 52 | 73 | 26 |
Peripheral arterial disease | 1 | 2 | 3 | 4 | 6 | 8 | 10 | 13 | 16 | 25 | 8 |
Atrial fibrillation | 3 | 5 | 7 | 9 | 10 | 13 | 16 | 21 | 29 | 43 | 15 |
Stroke | 0 | 1 | 1 | 2 | 3 | 5 | 8 | 14 | 22 | 39 | 9 |

Non-CVD comorbidities (%)

Chronic kidney disease | 2 | 2 | 3 | 4 | 4 | 5 | 7 | 9 | 12 | 20 | 7 |
Chronic obstructive pulmonary disease | 20 | 20 | 20 | 21 | 22 | 23 | 25 | 27 | 28 | 30 | 23 |
Cancer | 4 | 5 | 6 | 7 | 8 | 9 | 11 | 13 | 14 | 12 | 9 |
Chronic liver disease | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

Psychosocial characteristics

Depression at diagnosis (%) | 20 | 17 | 15 | 15 | 14 | 14 | 15 | 17 | 18 | 21 | 17 |
Anxiety at diagnosis (%) | 7 | 6 | 6 | 7 | 7 | 8 | 8 | 10 | 12 | 8 |

Biomarkers

Heart rate (bpm) | 72 | 71 | 71 | 71 | 71 | 71 | 72 | 73 | 74 | 76 | 72 |
Creatinine (mmol/L) | 88 | 92 | 95 | 96 | 98 | 100 | 101 | 104 | 109 | 125 | 100 |
White cell count (10^9/L) | 6.81 | 7.05 | 7.19 | 7.31 | 7.44 | 7.54 | 7.62 | 7.76 | 7.88 | 8.22 | 7.46 |
Haemoglobin (g/100 mL) | 1.43 | 1.43 | 1.42 | 1.41 | 1.39 | 1.37 | 1.35 | 1.32 | 1.28 | 1.22 | 1.36 |

Deprivation measured by index of multiple deprivation, 2010. All values in table are means. Percentage of missing data imputed: smoking status 32%, total cholesterol 54%, HDL 55%, heart rate 78%, creatinine 38%, white cell count 56% and haemoglobin 53%.

CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; stable-CAD, stable coronary artery disease; STEMI, ST segment elevation myocardial infarction.

follow-up in the CALIBER dataset (10 years) was based on age/sex-specific non-CVD mortality from national life tables.

These risk equations were developed into cumulative incidence functions which were then combined using a competing risks framework to account for the interdependence of the outcomes. We used methods outlined by Putter et al.\(^\text{21}\) that acknowledge state transition probabilities are affected by the event being modelled and also by the other events that could occur from a given health state. Survival models were estimated using \(R\) (V.3.1.0) and the \(R\) package \texttt{flexsurv} (V.0.3).

**Resource use and costs**

Healthcare resource use was estimated directly from the CALIBER dataset. A panel was constructed using a 90-day cycle length for patients with stable-CAD in CALIBER capturing resource use in terms of hospital episodes, use of drugs, diagnostic tests and primary care consultations. Costs were attached to this resource use using the NHS reference costs,\(^\text{22}\) NHS prescription cost analysis\(^\text{23}\) and Personal Social Services Research Unit (PSSRU) unit costs for primary care\(^\text{24}\) datasets. All costs were calculated from a health systems perspective and based on the price year 2011/2012. Panel data models were used to estimate patient costs adjusted for the prognostic factors used in the model, as well as for the key CVD events in the model. This allowed us to attach costs to model states adjusted for baseline patient characteristics and event history.

**Health-related quality of life**

HRQoL estimates were not available from the CALIBER dataset. Instead a catalogue of EQ-5D scores for the UK\(^\text{25}\) was used to calculate age-specific, condition-specific and event-specific HRQoL. These were attached to states in the model to calculate patient-specific estimates of remaining lifetime QALYs.

**Analysis**

Given that the model was designed to be used with a heterogeneous population, results were produced stratified by risk group. The 5 year baseline risk of experiencing at least one CVD event for each patients with stable-CAD in the CALIBER dataset was predicted based on the estimated risk equations given the patient’s baseline covariate values as input parameters. The baseline values were those from the prognostic factors used in the risk equations measured at the point that the patient entered into the stable-CAD cohort. Patients were ranked by risk predictions and grouped into 10 equally sized risk groups. Model results were calculated at the mean baseline covariate value across patients within each risk group. In addition, estimates were predicted for a representative patient within each of the 10 risk groups demonstrating both the population-level and patient-level results produced by the model. The model was evaluated probabilistically by means of a Monte Carlo simulation run for 1000 iterations in order to incorporate and characterise the uncertainty in the model inputs.\(^\text{26}\)

---

**Figure 2** Proportion of patients in each of the six model states over time as predicted by the Markov model used in this study. Each plot within the panel represents a risk decile as categorised by the baseline 5-year CVD event risk ranging from the lowest risk decile (1) to the highest risk decile (10). As can be seen in the plots the model is run until all the patients in the cohort have experienced either a fatal CVD or a fatal non-CVD event. CVD, cardiovascular disease; MI, myocardial infarction.
The model was used to calculate life expectancy, QALYs, total healthcare costs and CVD-specific healthcare costs for standard care, as well as for indicative new treatments assumed to reduce CVD risks by 10%, 20%, 30% and 40%. The indicative treatments were assumed to have constant costs and treatment effects, no direct effect on the risk of non-CVD mortality and no side-effects. When interpreting the results of this analysis it should be recognised that these assumptions may not hold in practice. The results were used to estimate the maximum price that could be charged for the new treatments in each of the risk groups assuming a range of cost-effectiveness thresholds between £10 000 and £40 000 per QALY. National Institute for Health and Care Excellence (NICE) employ a threshold ranging between £20 000 and £30 000 per QALY for considering an intervention cost-effective in England, and patients had 2.8 remaining expected discounted QALYs.

Further details about the (a) patients with stable-CAD in the CALIBER dataset, (b) the economic model, (c) the estimation of costs and transition probabilities for use in the model, (d) the risk equations used to estimate model transition probabilities, (e) patient profiles for the 10 representative patients and (f) extended tables of results can be found in the accompanying online supplementary material appendices. The full model source code detailing all calculations performed in the model, including the model input parameters for the 10 risk groups and 10 representative patients as well as detailed instructions on how to run the model, are available from: https://github.com/miqdadasaria/caliber-scad-model.

RESULTS
The average baseline patient covariates by risk group are shown in table 1. For the cohort, the mean age at cohort entry was 67 years for males and 72 years for females. Stable angina (47%) was the most frequent stable-CAD subgroup and STEMI (7%) the least. One in 10 patients had PCI within the previous 6 months, over a quarter had heart failure, nearly one in five had depression at the time of stable-CAD diagnosis and one in six had atrial fibrillation.

There was large variation in CVD risk between the lowest and highest risk groups, with an absolute difference in 5-year risk between the lowest and highest risk group of 40.7%. The risk of clinical events positively correlated with age, higher levels of CVD risk factors (such as hypertension and diabetes) and higher prevalence of CVD comorbidities. There were no obvious trends in the key modifiable CVD risk factors such as the lipid profile.

The modelled progression of CVD over time by risk group is shown in figure 2. Higher risk groups were predicted to have much higher levels of CVD mortality compared with lower risk groups, whereas the latter were predicted to remain event free for a much longer period and were more likely to die of non-CVD-related causes.

Summary model results by risk group are shown in table 2. The risk of all non-fatal events increased with overall CVD risk, and the risk of non-CVD mortality declined with overall CVD risk. Lower risk patients were estimated to have greater remaining life expectancy, QALYs and healthcare costs. For low risk patients (5-year CVD risk 3.5%), the remaining expected discounted lifetime healthcare costs were £62 210, and patients had 12.0 expected discounted QALYs remaining. For the highest risk group (5-year CVD risk 44.2%), the remaining expected discounted lifetime healthcare costs were £35 549, and patients had 2.8 remaining expected discounted QALYs.

Figure 3 shows the maximum price that the health system should be willing to pay for new treatments targeted at each risk group.
group that reduce CVD hazards by between 10% and 40%. This maximum price increased with both increasing baseline risk and with larger treatment effects in terms of proportionate risk reduction.

More detailed breakdowns of these results as well as results presented for the representative patients drawn from each risk group can be found in online supplementary appendix (f).

DISCUSSION

We report the first comprehensive lifetime model of stable-CAD based on long-term EHR data. The model encompasses a full range of CVD endpoints and accounts for the interdependence of CVD risks among patients with stable-CAD. The sample sizes, duration of follow-up and the large number of endpoints and risk factors captured by the multisource EHR dataset (CALIBER) provided the opportunity to build a model which more fully and accurately captured the biological and medical nuances of such a condition. In quantifying the expected costs, life expectancy and quality-adjusted life expectancy of patients with stable-CAD, this analysis provides a means to plan budgets and services for such patients in the NHS in particular, and in health systems in developed countries more generally.

We found that at NICE’s lower bound cost-effectiveness threshold (£20 000 per QALY), a treatment aimed at the lowest risk patients (5-year risk of 3.5%), would be cost-effective with annual prices up to £36, £72, £108 or £143 if the treatment was able to reduce CVD risk by 10%, 20%, 30% and 40%, respectively. For the highest risk patients (5-year risk of 44.2%), the respective maximum prices would be £325, £645, £961 or £1269. For comparison, statins commonly used by these patients reduce CVD risk by approximately a third and cost £16 per patient per year, whereas the annual cost of new anti-platelet agents can be up to £712 per patient per year. These estimates provide a basis for developers of new medications and health technologies for stable-CAD to define necessary effect sizes that they will need to demonstrate to be considered value for money by health systems.

In this study it has been shown that using EHR data, in combination with an analytical model such as that used by NICE in the English NHS, provides a powerful framework within which to assess the cost-effectiveness of new technologies. In the many healthcare systems with constrained budgets, cost-effectiveness analysis provides a means of comparing the additional health benefits from a new intervention with the health other patients forgo because expenditure on other types of treatments is necessarily curtailed in order to finance the new intervention (opportunity costs). The current analysis uses this approach as a basis for identifying the minimum treatment effect a new intervention for stable-CAD will have to achieve at a given price (or the maximum price for a given treatment effect) and cost-effectiveness threshold. These necessary treatment effects and prices will inevitably vary according to patients’ underlying risk of CVD events.

There are very few comparable studies that focus on modelling the costs and health effects over the lifetime of patients with stable-CAD. Studies that we are aware of in this area are typically based on short-term trial data, model only a subset of...
the relevant CVD endpoints and make predictions over short time horizons. Models suitable for the economic evaluation of health technologies in disease areas such as CVD where there are substantial mortality impacts need to estimate all relevant healthcare costs and health outcomes over the remaining lifetimes of patients. This is why in our study, despite having 10 years of follow-up data, we still required a model to extrapolate up to a maximum of 60 years beyond our data to estimate total lifetime costs and consequences for the full cohort of modelled patients. Limitations of our study are that HRQoL data were not recorded in the CALIBER dataset and so had to be drawn from external studies; that changes in prognostic risk factors over time were not explicitly modelled; instead the equations underpinning our model were informed by the baseline values of these risk factors; the dataset we used did not contain left ventricular ejection fraction which is an important prognostic factor in this patient population; and that the long follow-up period of our dataset may mean that the modelled risk equations may not fully reflect contemporary risk levels in the population. Additionally a number of structural assumptions had to be made for modelling purposes and these are detailed in online supplementary appendix (b).

The model we have produced allows policy makers to quantify and understand both the health and the cost burden of stable-CAD and serves as a basis for evaluating the cost-effectiveness of new treatments targeted at reducing CVD risk in this population. Our results suggest that, for the vast majority of patients with stable-CAD, it is likely that low cost interventions to improve adherence to existing secondary prevention drugs should be prioritised over high cost new treatments. It is also notable from our results that, even among the groups with the highest CVD risk, more patients are predicted to die of non-CVD-related causes than of CVD-related causes. This highlights the vital role of primary care in the holistic management of both CVD and non-CVD risk for these patients.

**Key messages**

**What is already known on this subject?**
- Electronic health records have been shown to be useful in prognosis, but thus far their use in decision analytic models and cost-effectiveness analysis has been limited.
- The recent improvement in acute coronary syndrome survivorship means that a growing number of people are living with cardiovascular disease.

**What might this study add?**
- This study provides the first lifetime model of the costs and health effects of patients with stable coronary artery disease based on long-term linked electronic health records, predicting key cardiovascular endpoints for these patients and capturing the interdependence of these endpoints.

**How might this impact on clinical practice?**
- This model can be used to evaluate and to target appropriately new treatments as they emerge for this patient population as well as to inform commissioning, pricing and reimbursement decisions.

Acknowledgements The authors would like to acknowledge the following people for help in understanding the CALIBER dataset and prognostic models: Eleni Rapsomaniki, Pablo Perez, Spiros Denaxas, Katja Grasic, Julie George, Owen Nicholas, Ruzan Udimyan, Gene Feder, Aroon Hingorani, Spiros Denaxas, Julie George, Emily Herrett, Dipak Kalra, Aroon Hingorani, Mike Kivimaki and Liam Smeeth. This work made use of the facilities of N8 HPC provided and funded by the N8 consortium and EPSRC (Grant No. EP/K000225/1). The Centre is coordinated by the Universities of Leeds and Manchester.

**Contributors** MA conducted the main data analysis and drafted and revised the paper and is the guarantor of the study, SW, SP and MS advised on health economic issues and helped to design the model. ADS, CPG, AT and HH advised on clinical issues. KRA, MC and AM advised on statistical issues. AT and HH were responsible for the overall grant from the NIHR. All authors commented on drafts of the paper. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MA affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

**Funding** The study was funded by the UK National Institute for Health Research (NIHR) (RP-PG-0407-10314) and the Wellcome Trust (WT 086091/2/08/2) and was supported by the Farr Institute of Health Informatics Research, funded by The Medical Research Council (K006584/1) in partnership with Arthritis Research UK, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Engineering and Physical Sciences Research Council, the NIHR, the National Institute for Social Care and Health Research (Welsh Assembly Government), the Chief Scientist Office (Scottish Government Health Directors) and the Wellcome Trust. CPG is funded by the National Institute for Health Research (NIHR-CTF-2014-03-03) as associate professor and honorary consultant cardiologist. MC is partly funded by a National Institute for Health Research Doctoral Fellowship (DRF-2012-05-409). ADS is funded by a Wellcome Trust Clinical Research Training Fellowship (093830/Z/10/Z). KRA and MS are partially supported by the National Institute for Health Research as senior investigators (NF-S-0512-10159 and NF-S-0513-10060, respectively). The funding bodies did not play any role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The views expressed in this publication are those of the authors.

**Competing interests** All authors have completed the Unified Competing Interests form at http://www.icmje.org/coiDisclosure.pdf (available on request from the corresponding author) and declare that MA, SW, SP, CPG, ADS, MC and HH have nothing to disclose. AM reports payments from Menarini Pharmaceuticals, other from Servier, outside the submitted work. KRA reports personal fees from ABPI, Roche, Novo Nordisk, AstraZeneca, Janssen, Allergan, outside the submitted work.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** An extensive supplementary appendix with additional analyses has been submitted alongside the paper and the model source code and instructions on how to use to reproduce the results in the paper are available at https://github.com/miqdadasaria/caliber-scad-model.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

**REFERENCES**

Coronary artery disease


Using electronic health records to predict costs and outcomes in stable coronary artery disease

Migdad Asaria, Simon Walker, Stephen Palmer, Chris P Gale, Anoop D Shah, Keith R Abrams, Michael Crowther, Andrea Manca, Adam Timmis, Harry Hemingway and Mark Sculpher

*Heart* published online February 10, 2016

Updated information and services can be found at: http://heart.bmj.com/content/early/2016/02/10/heartjnl-2015-308850

**These include:**

**Supplementary Material**

Supplementary material can be found at: http://heart.bmj.com/content/suppl/2016/02/10/heartjnl-2015-308850.DC1.html

**References**

This article cites 22 articles, 11 of which you can access for free at: http://heart.bmj.com/content/early/2016/02/10/heartjnl-2015-308850#BIBL

**Open Access**

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (159)
- Drugs: cardiovascular system (8566)
- Health policy (219)
- Acute coronary syndromes (2663)

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/